Class summary at a glance.

Every drug in the Integrin Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $338.9Mcombined across class
Total Rx claims: 40K9K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Vedolizumab

Brand: ENTYVIO · 33K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2014-05-20

Brand-only (no generics) 64 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $277.0M

Class share

82%

of class CY24 spend

View profile →

Natalizumab

Brand: TYSABRI · 7K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2004-11-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $61.9M

Class share

18%

of class CY24 spend

View profile →

Natalizumab-Sztn

Brand: TYRUKO · — Part D claims (CY24) · First FDA approval: 2025-11-17

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.